We thank Dr Shults for his interest in the TEMPO study,1 which incorporated a randomized, delayed-start design to help differentiate short-term symptomatic effects of rasagiline from more durable, disease-modifying effects.2 As in the Coenzyme Q10 trial in early Parkinson disease,3 the total Unified Parkinson’s Disease Rating Scale (UPDRS) score was prespecified as the primary measure of efficacy.
Siderowf A, Eberly S, Oakes D, Shoulson I, Parkinson Study Group TEMPO Steering Committee. Reexamination of the TEMPO Study—Reply. Arch Neurol. 2005;62(8):1321. doi:10.1001/archneur.62.8.1321